New Issue: Marshall Edwards gets equity line, sells $4 million of stock

By Sheri Kasprzak

New York, July 12 - Marshall Edwards, Inc. sealed a $15 million equity line agreement with Cornell Capital Partners, LP.

Under the two-year agreement, Cornell may buy shares of Marshall Edwards at 97% of the lowest volume weighted average price over the five consecutive trading days after notice of a draw.

Connected to the offering, Cornell received warrants for 600,000 shares, exercisable at $4.35 each through July 11, 2010.

Separately, Cornell bought 1,379,310 shares at $2.90 each and received warrants for 482,759 shares, exercisable at $4.35 each through July 11, 2010.

Based in North Ryde, New South Wales, Australia, Marshall Edwards is a pharmaceutical company focused on developing treatments for cancer.

Equity line

Issuer:	Marshall Edwards, Inc.
Issue:	Equity line
Amount:	$15 million
Tenor:	Two years
Price:	97% of the lowest VWAP over the five trading days after notice of a draw
Warrants:	For 600,000 shares
Warrant expiration:	July 11, 2010
Warrant strike price:	$4.35
Investor:	Cornell Capital Partners, LP
Settlement date:	July 11
Stock symbol:	Nasdaq: MSHL
Stock price:	$3.58 at close July 11
Stock
Issuer:	Marshall Edwards, Inc.
Issue:	Stock
Amount:	$4 million
Shares:	1,379,310
Price:	$2.90
Warrants:	For 482,759 shares
Warrant expiration:	July 11, 2010
Warrant strike price:	$4.35
Investor:	Cornell Capital Partners, LP
Settlement date:	July 11
Stock symbol:	Nasdaq: MSHL
Stock price:	$3.58 at close July 11

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.